Multicenter phase 3 study of CNS activitity of first-line furmonertinib versus gefitinib in patients with EGFR-mutated advanced NSCLC

Furmonertinib (AST2818) is a third-generation EGFR-TKI. The phase 3 FURLONG study, at 55 centers in China, compared first-line furmonertinib versus the first-generation EGFR-TKI gefinitib for EGFR mutated locally advanced or metastatic NSCLC. Among the 358 patients in the study, 133 (37%) had CNS metastases. Prespecified analysis found that first-line furmonertinib compared with gefitinib had superior CNS efficacy among patients with CNS metastases from EGFR mutated NSCLC.